Esperion Therapeutics, Inc. (NASDAQ:ESPR) Stock Position Lifted by Barclays PLC

Barclays PLC lifted its stake in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) by 99.6% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 309,671 shares of the biopharmaceutical company’s stock after purchasing an additional 154,509 shares during the quarter. Barclays PLC owned about 0.16% of Esperion Therapeutics worth $510,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of ESPR. Public Employees Retirement System of Ohio bought a new stake in shares of Esperion Therapeutics during the 3rd quarter worth about $606,000. Anson Funds Management LP bought a new stake in Esperion Therapeutics during the third quarter worth approximately $540,000. Connor Clark & Lunn Investment Management Ltd. lifted its position in Esperion Therapeutics by 71.0% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 711,278 shares of the biopharmaceutical company’s stock worth $1,174,000 after purchasing an additional 295,378 shares during the period. Wellington Management Group LLP boosted its stake in Esperion Therapeutics by 66.8% during the 3rd quarter. Wellington Management Group LLP now owns 602,936 shares of the biopharmaceutical company’s stock valued at $995,000 after purchasing an additional 241,512 shares in the last quarter. Finally, Wasatch Advisors LP increased its position in shares of Esperion Therapeutics by 38.4% during the 3rd quarter. Wasatch Advisors LP now owns 23,346,013 shares of the biopharmaceutical company’s stock valued at $38,521,000 after purchasing an additional 6,483,070 shares during the period. Institutional investors and hedge funds own 47.39% of the company’s stock.

Esperion Therapeutics Trading Down 2.2 %

Shares of NASDAQ:ESPR opened at $2.21 on Friday. The firm has a market cap of $435.46 million, a price-to-earnings ratio of -3.45, a P/E/G ratio of 0.17 and a beta of 1.03. Esperion Therapeutics, Inc. has a 1 year low of $1.58 and a 1 year high of $3.94. The business has a fifty day simple moving average of $2.47 and a 200 day simple moving average of $2.18.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the company. Cantor Fitzgerald assumed coverage on Esperion Therapeutics in a research note on Tuesday, December 17th. They set an “overweight” rating and a $8.00 target price for the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $6.00 price objective on shares of Esperion Therapeutics in a research note on Friday, December 13th. The Goldman Sachs Group began coverage on shares of Esperion Therapeutics in a report on Wednesday, December 18th. They issued a “neutral” rating and a $4.00 target price on the stock. StockNews.com cut shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Esperion Therapeutics in a report on Friday, January 10th. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $7.30.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.